ATE214945T1 - Verwendung von nk-1 receptor antagonisten mit opioid-analgetika - Google Patents

Verwendung von nk-1 receptor antagonisten mit opioid-analgetika

Info

Publication number
ATE214945T1
ATE214945T1 AT95940386T AT95940386T ATE214945T1 AT E214945 T1 ATE214945 T1 AT E214945T1 AT 95940386 T AT95940386 T AT 95940386T AT 95940386 T AT95940386 T AT 95940386T AT E214945 T1 ATE214945 T1 AT E214945T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
opioid analgesics
nociception
morpholine
administering
Prior art date
Application number
AT95940386T
Other languages
English (en)
Inventor
Raymond George Hill
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE214945T1 publication Critical patent/ATE214945T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95940386T 1994-12-23 1995-12-15 Verwendung von nk-1 receptor antagonisten mit opioid-analgetika ATE214945T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9426102.1A GB9426102D0 (en) 1994-12-23 1994-12-23 Pharmacuetical compositions
PCT/GB1995/002931 WO1996020009A1 (en) 1994-12-23 1995-12-15 Use of a tachykinin antagonist and an opioid analgesic

Publications (1)

Publication Number Publication Date
ATE214945T1 true ATE214945T1 (de) 2002-04-15

Family

ID=10766509

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95940386T ATE214945T1 (de) 1994-12-23 1995-12-15 Verwendung von nk-1 receptor antagonisten mit opioid-analgetika

Country Status (10)

Country Link
US (2) US5880132A (de)
EP (1) EP0799056B1 (de)
JP (1) JPH11500104A (de)
AT (1) ATE214945T1 (de)
AU (1) AU705523B2 (de)
CA (1) CA2207650A1 (de)
DE (1) DE69526115T2 (de)
ES (1) ES2173986T3 (de)
GB (1) GB9426102D0 (de)
WO (1) WO1996020009A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317987D0 (en) * 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
GB9513117D0 (en) * 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
US6271230B1 (en) * 1997-12-01 2001-08-07 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating cognitive disorders
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
JP2001526229A (ja) * 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド投薬剤形の乱用を防止する方法
PT1041987E (pt) * 1997-12-22 2006-07-31 Euro Celtique Sa Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
AU4334900A (en) * 1999-04-09 2000-11-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
US6225343B1 (en) 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
SK18172001A3 (sk) 1999-06-16 2002-07-02 Nastech Pharmaceutical Co., Inc. Farmaceutické preparáty obsahujúce morfín a spôsoby ich intranazálneho podávania
SI2517710T1 (sl) * 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
DK1416842T3 (da) * 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003013525A1 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
BRPI0212298B8 (pt) * 2001-09-03 2021-05-25 Newron Pharm Spa composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
WO2003078448A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
US20050245483A1 (en) 2002-04-05 2005-11-03 Bianca Brogmann Matrix for sustained, invariant and independent release of active compounds
PL205811B1 (pl) * 2002-08-13 2010-05-31 Iwona Bonney Zastosowanie peptydów o działaniu analgetycznym jako substancji czynnej w urządzeniach do podawania leku bezpośrednio do miejsca ich spodziewanego działania przeciwbólowego
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
JP2006527236A (ja) 2003-06-10 2006-11-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ オピオイド鎮痛薬と組合せた置換１，４−ジ−ピペリジン−４−イル−ピペラジン誘導体ならびに疼痛およびオピオイドに基づく処置に伴う副作用の処置のためのそれらの使用
WO2004110451A1 (en) * 2003-06-10 2004-12-23 Janssen Pharmaceutica N.V. Combinations for opioid-based treatment of pain comprising 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
CA2577408C (en) * 2004-09-10 2013-07-09 Elena Barbanti Use of (halobenzyloxy) benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1843734A4 (de) * 2005-02-03 2008-09-10 Signum Biosciences Inc Zusammensetzungen und verfahren zur intensivierung kognitiver funktionen
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
JP5078869B2 (ja) * 2005-03-08 2012-11-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ニューロキニン（ｎｋ１）拮抗物質としてのジアザ−スピロ−［４．４］−ノナン誘導体
WO2007039883A2 (en) 2005-10-05 2007-04-12 Ranbaxy Laboratories Limited Process for preparation of aprepitant
RU2397160C9 (ru) * 2005-12-22 2012-10-27 НЬЮРОН ФАРМАСЬЮТИКАЛЗ С.п.А. 2-фенилэтиламинопроизводные в качестве модуляторов кальциевых и/или натриевых каналов
SI2034975T1 (sl) * 2006-06-19 2012-07-31 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
WO2008064317A1 (en) * 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2709992A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Abuse resistant pharmaceutical compositions of opiod agonists
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
WO2009132051A1 (en) 2008-04-21 2009-10-29 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
JP5406288B2 (ja) * 2008-07-07 2014-02-05 ユーロ−セルティーク エス．エイ． 尿閉を治療するためのオピオイド拮抗薬の使用
CA2730745A1 (en) 2008-07-17 2010-01-21 Merial Limited Long-acting injectable analgesic formulations for animals
ME03298B (de) 2009-03-10 2019-07-20 Euro Celtique Sa Oxycodon und naloxon enthaltende pharmazeutische zusammensetzung mit sofortiger freisetzung
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US20190083460A1 (en) * 2016-03-16 2019-03-21 Zeno Royalties & Milestones, LLC Analgesic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0551386T3 (da) 1990-10-05 2004-05-10 Genencor Int Fremgangsmåde til behandling af bomuldsholdige stoffer med cellulase
DE69231395T3 (de) * 1991-09-20 2005-07-21 Glaxo Group Ltd., Greenford Neue medizinische Indikation für Tachykinin-Antagonisten
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5891842A (en) 1993-04-09 1999-04-06 Trustees Of Tufts College Methodology for eliciting an analgesic response in a living subject

Also Published As

Publication number Publication date
US6180624B1 (en) 2001-01-30
ES2173986T3 (es) 2002-11-01
GB9426102D0 (en) 1995-02-22
US5880132A (en) 1999-03-09
AU4185496A (en) 1996-07-19
JPH11500104A (ja) 1999-01-06
WO1996020009A1 (en) 1996-07-04
CA2207650A1 (en) 1996-07-04
AU705523B2 (en) 1999-05-27
EP0799056B1 (de) 2002-03-27
EP0799056A1 (de) 1997-10-08
DE69526115D1 (de) 2002-05-02
DE69526115T2 (de) 2002-10-02

Similar Documents

Publication Publication Date Title
ATE214945T1 (de) Verwendung von nk-1 receptor antagonisten mit opioid-analgetika
DK0760661T3 (da) Farmaceutiske sammensætninger omfattende en opiat-antagonist og calciumsalte, deres anvendelse til behandling af endorfin-m
HU9503826D0 (en) Heterocycles useful as neurokinin antagonists
EP0871488A4 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu-opioidanagonisten und eines kappa - 2- opioidanagonisten
HUT76644A (en) Substituted piperidines, pharmaceutical compositions containing them and their use
ES8505519A1 (es) Un procedimiento para la preparacion de 14-fluoromorfinanos utiles como analgesicos, narcoticos y-o agentes anorexicos.
ATE301994T1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda- antagonist
ATE147385T1 (de) Chinuclidin derivat als substanz p antagonist
HUT74992A (en) Use of serotonin antagonist indol derivatives for producing pharmaceutical compositions using for treating fibromyalgia
MX9602818A (es) Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
MX9703889A (es) Peptido rantes y fragmentos y composiciones que lo contienen, para el tratamiento de la inflamacion.
NZ337827A (en) Use of GluR5 receptor antagonists in the manufacture of medicaments for treating pain
ATE240730T1 (de) Verwendung von levobupivacaine in gesichtschirugie
ATA903796A (de) Elektrotransporteinrichtung zur verabreichung eines als fentanylsalz oder als sufentanilsalz vorliegenden analgetischen medikaments
ATE234359T1 (de) Fusionsproteine bestehend aus gewebefaktor- kunitzdomäne als inhibitoren des faktors viia
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
DE69733557D1 (de) Endothelin-antagonisten zur behandlung von herzversagen
MX9603045A (es) Antagonistas de los receptores endoteliales.
DE69732133D1 (de) Verfahren und vorrichtung zur kompensation von durch chrominanzsignalverarbeitung verursachten luminanzstörungen
DE69123580D1 (de) Verwendung von antagonisten des plättchen-aktivierenden faktors bei pruritus
NO964670L (no) Nye opioidpeptidanaloger med blandete my agonist/ antagonist-egenskaper
DE69730515D1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlungen von stress störungen
IL143143A0 (en) USE OF A 5HT2A AND 5HT2A/C RECEPTOR ANTAGONIST FOR PREPARING MEDICINES FOR TREATING SNORING AND HIGH RESISTAnCE SYNDROME OF UPPER ANATOMICAL AIRWAYS
EP0672413A4 (de) Neue verwendung von (+)-2-nitroxyethyl-apovincaminat.
ZA903015B (en) Therapeutic use of 5-ht3 receptor antagonists

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties